Scholarlink

Background <p>Cervical cancer ranks as the fourth most common malignancy in women globally.<sup><CitationRef CitationID="CR1">1</CitationRef></sup> For early stage disease, radical hysterectomy with pelvic lymphadenectomy remains the standard surgical approach. The LACC trial revealed that minimally invasive surgery (MIS) was associated with inferior oncologic outcomes compared with open surgery,<sup><CitationRef CitationID="CR2">2</CitationRef></sup> with this discrepancy largely attributed to the compromise of tumor-free principles during MIS—particularly through the use of uterine manipulators that may cause mechanical tumor compression and dissemination.<sup><CitationRef CitationID="CR3">3</CitationRef></sup> While open surgery is generally preferred, MIS may be considered in selected cases, such as tumors ≤ 2&#xa0;cm according to Chinese guidelines.<sup><CitationRef CitationID="CR4">4</CitationRef></sup></p> Patients and Methods <p>To address these concerns, we developed a tumor-free technique incorporating Ma’s suspending band and tumor-shielded vaginal closure, adapted for robotic single-site radical hysterectomy using the da Vinci Xi platform.</p> Results <p>Key features include: (1) ergonomic single-site access through a 3–4&#xa0;cm umbilical incision accommodating a quad-channel port, enabling simultaneous operation of three robotic arms while preserving a dedicated assistant channel for traction, suction, and irrigation; (2) optimized pneumoperitoneum management through strategic robotic arm positioning that elevates the abdominal wall, ensuring consistent surgical exposure at reduced intra-abdominal pressures (8–10&#xa0;mmHg versus conventional 12–14&#xa0;mmHg); (3) minimal parietal trauma through a single-incision approach that improves cosmetic outcomes and potentially reduces port-related complications.</p> Conclusions <p>This video article details the technical execution of our procedure, highlighting its reproducibility and adherence to oncological safety principles. Prospective data collection and follow-up are ongoing to evaluate long-term oncologic outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Application of Tumor-Free Technique in Robotic Single-Site Radical Hysterectomy for Early Stage Cervical Cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月5日

查看全文
  • Qiao Wang,
  • Mengchan Su,
  • Ying Zheng

摘要

Background

Cervical cancer ranks as the fourth most common malignancy in women globally.1 For early stage disease, radical hysterectomy with pelvic lymphadenectomy remains the standard surgical approach. The LACC trial revealed that minimally invasive surgery (MIS) was associated with inferior oncologic outcomes compared with open surgery,2 with this discrepancy largely attributed to the compromise of tumor-free principles during MIS—particularly through the use of uterine manipulators that may cause mechanical tumor compression and dissemination.3 While open surgery is generally preferred, MIS may be considered in selected cases, such as tumors ≤ 2 cm according to Chinese guidelines.4

Patients and Methods

To address these concerns, we developed a tumor-free technique incorporating Ma’s suspending band and tumor-shielded vaginal closure, adapted for robotic single-site radical hysterectomy using the da Vinci Xi platform.

Results

Key features include: (1) ergonomic single-site access through a 3–4 cm umbilical incision accommodating a quad-channel port, enabling simultaneous operation of three robotic arms while preserving a dedicated assistant channel for traction, suction, and irrigation; (2) optimized pneumoperitoneum management through strategic robotic arm positioning that elevates the abdominal wall, ensuring consistent surgical exposure at reduced intra-abdominal pressures (8–10 mmHg versus conventional 12–14 mmHg); (3) minimal parietal trauma through a single-incision approach that improves cosmetic outcomes and potentially reduces port-related complications.

Conclusions

This video article details the technical execution of our procedure, highlighting its reproducibility and adherence to oncological safety principles. Prospective data collection and follow-up are ongoing to evaluate long-term oncologic outcomes.